Cross-Linked Hyaluronate Gel for Dry Eye Syndrome
(LaReCa Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This trial tests a special gel treatment for individuals with dry eye syndrome. The gel, called Cross-Linked Hyaluronate Gel, is applied to the tear ducts before cataract surgery to determine if it helps maintain eye moisture. Those diagnosed with dry eye disease who experience short-lasting tears may be suitable candidates. Participants should also be considering advanced lens implants as part of their cataract procedure. As an unphased trial, this study provides a unique opportunity to explore a new treatment option for dry eye syndrome.
Do I need to stop my current medications for this trial?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial team or your doctor.
What prior data suggests that this gel is safe for use in cataract surgery patients?
Research has shown that cross-linked hyaluronate gel is safe for treating dry eye syndrome. Studies have found no serious side effects from hyaluronic acid, a main ingredient in the gel. Previous research demonstrated that this treatment is well-tolerated and effective, providing relief from dry eyes for at least three months. This makes it a promising option for managing dry eye symptoms safely.12345
Why are researchers excited about this trial?
Unlike the standard treatments for dry eye syndrome, which often include artificial tears or anti-inflammatory drugs, cross-linked hyaluronate gel offers a unique approach by providing sustained ocular hydration. This treatment uses a cross-linked form of hyaluronate, a naturally occurring substance in the eye, to create a gel that can be applied directly to the tear ducts. This method not only prolongs the moisturizing effects but also minimizes the need for frequent applications. Researchers are excited because this could lead to a more convenient and potentially more effective solution for those suffering from dry eyes.
What evidence suggests that this cross-linked hyaluronate gel is effective for dry eye syndrome?
Research has shown that a special gel called cross-linked hyaluronate effectively treats dry eye syndrome. Studies have found that it greatly improves eye health by reducing redness, irritation, and discharge. In this trial, participants will receive bilateral lacrimal occlusion with cross-linked hyaluronate canalicular gel. The gel keeps the eye surface moist and protected, helping to lessen inflammation and dryness. It also provides benefits that last for at least three months. Overall, this method safely and effectively relieves dry eye symptoms.24678
Who Is on the Research Team?
Kayla Karpuk, OD
Principal Investigator
Vance Thompson Vision Clinic Prof. LLC
Vance Thompson, MD
Principal Investigator
Vance Thompson Vision Clinic Prof. LLC
Are You a Good Fit for This Trial?
This trial is for adults aged 22 or older with dry eye disease confirmed by an OSDI score of 13 or higher. Participants must be able to sign a consent form, have clear vision except for cataracts, and show tear instability. They should be willing to follow the study's procedures and visits, and suitable for advanced lens implants as per the investigator.Inclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Pre-operative Treatment
Patients receive bilateral lacrimal occlusion of crosslinked hyaluronate canalicular gel before cataract surgery
Post-operative Follow-up
Participants are monitored for changes in tear break-up time and overall eye health
What Are the Treatments Tested in This Trial?
Interventions
- Cross-Linked Hyaluronate Gel
Find a Clinic Near You
Who Is Running the Clinical Trial?
Vance Thompson Vision
Lead Sponsor